109 related articles for article (PubMed ID: 10360608)
21. Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
Recchia F; Lalli A; Lombardo M; De Filippis S; Saggio G; Fabbri F; Rosselli M; Capomolla E; Rea S
Cancer; 2001 Aug; 92(4):814-21. PubMed ID: 11550152
[TBL] [Abstract][Full Text] [Related]
22. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck.
Thödtmann F; Theiss F; Kemmerich M; Heinrich B; Laubenbacher C; Quasthoff S; Kau R; Herzog M; Diergarten K; Hanauske AR
Ann Oncol; 1998 Mar; 9(3):335-7. PubMed ID: 9602270
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.
Suzuki S; Ishikawa K
J Infect Chemother; 2009 Oct; 15(5):335-9. PubMed ID: 19856075
[TBL] [Abstract][Full Text] [Related]
24. Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group.
Muggia FM; Blessing JA; Homesley HD; Sorosky J
Cancer Chemother Pharmacol; 1998; 42(1):68-70. PubMed ID: 9619760
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Shin DM; Khuri FR; Glisson BS; Ginsberg L; Papadimitrakopoulou VM; Clayman G; Lee JJ; Ang KK; Lippman SM; Hong WK
Cancer; 2001 Apr; 91(7):1316-23. PubMed ID: 11283932
[TBL] [Abstract][Full Text] [Related]
26. Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer.
Pivot X; Wadler S; Kelly C; Ruxer R; Tortochaux J; Stern J; Belpomme D; Humblet Y; Domenge C; Clendeninn N; Johnston A; Penning C; Schneider M
Ann Oncol; 2001 Nov; 12(11):1595-9. PubMed ID: 11822760
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
Kim HS; Kim HR; Kim GM; Kim HS; Koh YW; Kim SH; Choi EC; Hong YK; Sung JH; Kim SM; Kim JH; Cho BC
Cancer Chemother Pharmacol; 2012 Oct; 70(4):539-46. PubMed ID: 22868340
[TBL] [Abstract][Full Text] [Related]
28. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
Cunningham D; Zalcberg JR; Rath U; Olver I; Van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
Eur J Cancer; 1995 Nov; 31A(12):1945-54. PubMed ID: 8562146
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Papadimitrakopoulou V; Lee JJ; Lawhorn K; Gillenwater AM; Ang KK; Clayman GL; Callender DL; Hong WK; Lippman SM
J Clin Oncol; 1998 Apr; 16(4):1325-30. PubMed ID: 9552033
[TBL] [Abstract][Full Text] [Related]
30. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
Pivot X; Raymond E; Laguerre B; Degardin M; Cals L; Armand JP; Lefebvre JL; Gedouin D; Ripoche V; Kayitalire L; Niyikiza C; Johnson R; Latz J; Schneider M
Br J Cancer; 2001 Sep; 85(5):649-55. PubMed ID: 11531245
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of Tomudex in relapsed epithelial ovarian cancer.
Gore ME; Earl HM; Cassidy J; Tattersall M; Mansi J; Seymour L; Azab M
Ann Oncol; 1995 Sep; 6(7):724-5. PubMed ID: 8664196
[No Abstract] [Full Text] [Related]
32. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Elser C; Siu LL; Winquist E; Agulnik M; Pond GR; Chin SF; Francis P; Cheiken R; Elting J; McNabola A; Wilkie D; Petrenciuc O; Chen EX
J Clin Oncol; 2007 Aug; 25(24):3766-73. PubMed ID: 17704426
[TBL] [Abstract][Full Text] [Related]
34. Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393).
Murphy BA; Leong T; Burkey B; Langer C; Forastiere A
Am J Clin Oncol; 2001 Feb; 24(1):64-6. PubMed ID: 11232952
[TBL] [Abstract][Full Text] [Related]
35. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
[TBL] [Abstract][Full Text] [Related]
36. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
[TBL] [Abstract][Full Text] [Related]
37. Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
Burgy M; Barthélémy P; Lefevre F; Dupret-Bories A; Truntzer P; Korenbaum C; Flesch H; Bronner G; Borel C
Oncology; 2017; 93(1):11-17. PubMed ID: 28423384
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.
Tseng JE; Glisson BS; Khuri FR; Shin DM; Myers JN; El-Naggar AK; Roach JS; Ginsberg LE; Thall PF; Wang X; Teddy S; Lawhorn KN; Zentgraf RE; Steinhaus GD; Pluda JM; Abbruzzese JL; Hong WK; Herbst RS
Cancer; 2001 Nov; 92(9):2364-73. PubMed ID: 11745292
[TBL] [Abstract][Full Text] [Related]
39. Ifosfamide in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck: a phase II Hoosier Oncology Group trial.
Sandler A; Saxman S; Bandealy M; Heilman D; Monaco F; McClean J; Arquette M
Am J Clin Oncol; 1998 Apr; 21(2):195-7. PubMed ID: 9537211
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
